Cadila Healthcare on Thursday (2 April 2020) said Zydus Cadila received final approval from the US drug regulator for Lamotrigine extended-release tablets.
The pharma major said Zydus Cadila received final approval from the United States Food and Drug Administration (USFDA) to market Lamotrigine extended-release tablets USP in multiple strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg.
The medication is indicated for treating certain types of seizures. It will be manufactured at the group manufacturing facility at SEZ, Ahmedabad (Gujarat).
The group now has 283 approvals and has so far filed over 386 Abbreviated New Drug Application (ANDA) since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare declined 1.22% to end at Rs 263.85 on 1 April 2020. BSE and NSE are shut today on account of Ram Navami.
On a consolidated basis, the drug maker's net profit fell 26.54% to Rs 375.18 crore on a 0.52% rise in net sales to Rs 3,534.50 crore in Q3 December 2019 Q3 December 2018.
Cadila Healthcare is a pharmaceutical company based in India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app